中国医药：子公司富马酸伏诺拉生原料药获批上市

Group 1 - The core point of the article is that Tianfang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of China National Pharmaceutical Group Corporation, has received approval from the National Medical Products Administration for the marketing application of fumaric acid volnoreline [1] - The drug is primarily used for the treatment of gastroesophageal reflux disease and the eradication of Helicobacter pylori [1] - As of the date of the announcement, the total investment in the research and development of the raw materials and formulations for this project is approximately 11.36 million yuan [1]